Premium
Gliotoxin treatment selectively spares M‐CSF‐ plus IL‐3‐responsive multipotent haemopoietic progenitor cells in bone marrow
Author(s) -
Kobayashi Masanobu,
Müllbacher Arno,
Waring Paul,
Hapel Andrew J.
Publication year - 1991
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1991.tb00542.x
Subject(s) - gliotoxin , bone marrow , progenitor cell , biology , immunology , stem cell , cancer research , microbiology and biotechnology , aspergillus fumigatus
Gliotoxin, an epipolythiodioxopiperazine, is a fungal metabolite that causes genomic DNA degradation preferentially in certain blood cell types including T lymphocytes and macrophages. Gliotoxin has previously been used to treat murine allogeneic bone marrow prior to transplantation into irradiated recipients, and in this situation the drug prevents development of graft‐versus‐host disease, and permits the establishment of allogeneic bone marrow chimeras. We have examined the nature of the cells that survive gliotoxin treatment and report here that gliotoxin selectively spares a unique class of haemopoietic stem cell that forms large (HPP) colonies in the presence of mixtures of M‐CSF and IL‐3. We confirm that the cells which survive gliotoxin treatment are capable of reconstituting the haemopoietic system in allogeneic lethally irradiated mice.